Deals Shaping the Medical Industry, January 2018

 
• By Beth Allan, Deanna Kamienski, and Maureen Riordan

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2017.

Dealmaking

Oxford Immunotec Global PLC and Qiagen NV have settled patent infringement litigation surrounding Qiagen's QuantiFERON-TB Gold and QuantiFERON-TB Gold Plus tests for tuberculosis. Under the settlement, Oxford received a payment of $27.5mm and granted Qiagen a royalty-free, non-exclusive license extending to current and future customers of the products. Qiagen gained the QuantiFERON in vitro diagnostic technology through its $355mm acquisition of Cellectis in 2011. The platform can provide information on the activity of the cell-mediated function of the immune system from whole blood samples. (Dec.)

Akers Biosciences Inc. (rapid in vitro point-of-care screening and testing products) netted $6.4mm through a follow-on public offering of...

More from Deal-Making

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.